日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial

Nirsevimab在日本婴儿中的安全性和药代动力学:开放标签JUBILUS试验的主要分析

Mori, Masaaki; Leach, Susannah; Learoyd, Maria; Vijapur, Divya; Sadow, Sam; Wilkins, Deidre; Abe, Yoshifusa; Ikeda, Kazushige; Kanegane, Hirokazu; Kano, Zempei; Moriuchi, Hiroyuki; Muneuchi, Jun; Nishikomori, Ryuta; Okazaki, Kaoru; Takas, Therese; Sakaguchi, Ayako; Villafana, Tonya

A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults

一项 I 期随机、安慰剂对照试验,旨在评估 nirsevimab 在健康中国成年人中的药代动力学、安全性和耐受性。

Mao, Xiaomeng; Hua, Xiaohan; Wu, Chengyi; Ge, Xiaoyun; Zhang, Jie; Wu, Xiaojie; Kubiak, Robert J; Wählby Hamrén, Ulrika; Villafana, Tonya; Christou, Georgios; Green, Jannine; Takas, Therese; Jin, Yuwen

Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season

接受单剂尼塞维单抗预防呼吸道合胞病毒感染的婴儿,在第二个呼吸道合胞病毒感染季中未出现病情加重的迹象。

Dagan, Ron; Hammitt, Laura L; Seoane Nuñez, Beatriz; Baca Cots, Manuel; Bosheva, Miroslava; Madhi, Shabir A; Muller, William J; Zar, Heather J; Chang, Yue; Currie, Alexander; Grenham, Amy; Shroff, Manish; Takas, Therese; Mankad, Vaishali S; Leach, Amanda; Villafana, Tonya

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

在患有心脏或肺部疾病的儿童中,于呼吸道合胞病毒(RSV)第二季流行前再次使用Nirsevimab的安全性

Domachowske, Joseph B; Chang, Yue; Atanasova, Victoria; Cabañas, Fernando; Furuno, Kenji; Nguyen, Kim A; Banu, Irfana; Kubiak, Robert J; Leach, Amanda; Mankad, Vaishali S; Shroff, Manish; Takas, Therese; Villafana, Tonya; Wählby Hamrén, Ulrika

Distinct phosphorylation states of mammalian CaMKIIβ control the induction and maintenance of sleep

哺乳动物 CaMKIIβ 的不同磷酸化状态控制睡眠的诱导和维持

Daisuke Tone, Koji L Ode, Qianhui Zhang, Hiroshi Fujishima, Rikuhiro G Yamada, Yoshiki Nagashima, Katsuhiko Matsumoto, Zhiqing Wen, Shota Y Yoshida, Tomoki T Mitani, Yuki Arisato, Rei-Ichiro Ohno, Maki Ukai-Tadenuma, Junko Yoshida Garçon, Mari Kaneko, Shoi Shi, Hideki Ukai, Kazunari Miyamichi, Takas

Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza

评估抗甲型流感单克隆抗体MEDI8852在治疗急性单纯性流感中的疗效

Ali, S Omar; Takas, Therese; Nyborg, Andrew; Shoemaker, Kathryn; Kallewaard, Nicole L; Chiong, Rafael; Dubovsky, Filip; Mallory, Raburn M

A Scoping Review of the Evidence on Health Promotion Interventions for Reducing Waterpipe Smoking: Implications for Practice

一项关于促进健康干预措施以减少水烟吸食的证据范围界定综述:对实践的启示

Gardner, Karen; Kearns, Rachael; Woodland, Lisa; Silveira, Mariela; Hua, Myna; Katz, Milena; Takas, Klara; McDonald, Julie

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

MEDI8897(一种长效单剂量呼吸道合胞病毒融合前F靶向单克隆抗体)在健康早产儿单次给药后的安全性、耐受性和药代动力学研究

Domachowske, Joseph B; Khan, Anis A; Esser, Mark T; Jensen, Kathryn; Takas, Therese; Villafana, Tonya; Dubovsky, Filip; Griffin, M Pamela

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

MEDI8897(一种具有延长半衰期的呼吸道合胞病毒融合前F靶向单克隆抗体)在健康成人中的安全性、耐受性和药代动力学

Griffin, M Pamela; Khan, Anis A; Esser, Mark T; Jensen, Kathryn; Takas, Therese; Kankam, Martin K; Villafana, Tonya; Dubovsky, Filip

An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

一种添加佐剂的、基于输血后F蛋白的疫苗未能预防老年人呼吸道合胞病毒感染

Falloon, Judith; Yu, Jing; Esser, Mark T; Villafana, Tonya; Yu, Li; Dubovsky, Filip; Takas, Therese; Levin, Myron J; Falsey, Ann R